Mixtures or organic compounds for the treatment of airway diseases

Abstract

A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.

1 .- 15 . (canceled) 
   
   
       16 . A method for the treatment of asthma which comprises administering by inhalation to a subject in need of such treatment a pharmaceutical composition comprising effective amounts of
 (a) a compound of formula (I)   
     
       
         
         
             
             
         
       
     
     in free or pharmaceutically acceptable salt or solvate form;
 (b) mometasone furoate; 
 
     and a pharmaceutically acceptable carrier, 
     wherein the molar ratio of (a) to (b) is from 5:1 to 1:10. 
   
   
       17 . A method according to  claim 16  wherein the pharmaceutical composition is a dry powder. 
   
   
       18 . A method according to  claim 17  wherein the average particle diameter of the dry powder is up to 10 μm. 
   
   
       19 . A method according to  claim 18  wherein the average particle diameter of 1 to 5 μm. 
   
   
       20 . A method according to  claim 16  wherein the pharmaceutically acceptable carrier is lactose monohydrate that has a particle diameter below 212 μm. 
   
   
       21 . A method according to  claim 16  wherein the molar ratio of (a) to (b) is from 3:1 to 1:7. 
   
   
       22 . A method according to  claim 16  wherein the molar ratio of (a) to (b) is from 2:1 to 1:2. 
   
   
       23 . A method according to  claim 16  wherein (a) is 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate.